Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy | Synapse
January 9, 2015Open Access
Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
Key Points
Key points are not available for this paper at this time.
Abstract
Pegfilgrastim is safe and significantly reduces the incidence of FN in breast cancer patients.